Phanes Therapeutics

Phanes Therapeutics announced that the USPTO granted patent US12,735,481 for its PACbody bispecific antibody technology platform. The company focuses on immuno-oncology drug discovery and development.

Phanes Therapeutics, Inc. received clearance from the US Food and Drug Administration to commence Phase I studies of PT199, its next-generation monoclonal antibody against CD73.

Phanes Therapeutics appointed Paul Chu as vice president of business development.

Phanes Therapeutics developed PACbody, a bispecific antibody platform that uses any pair of monoclonal antibodies while maintaining an IgG-like structure.

Phanes says its mission is to contribute to innovation in the biopharma industry and describes a working environment where scientists can pursue creative ideas.

Dirk Arnold is director of Asklepios Tumorzentrum Hamburg, an ESMO Council member, and a board member of the EORTC GI Cancer Group Steering Committee. Arnold is also an associate editor for Annals of Oncology and a member of the ESMO Open Editorial Board.

Ming Wang is founder, president and CEO of Phanes Therapeutics, Inc., based in San Diego. Ming formerly served as vice president and Disease Area Leader of Diabetes/Metabolism at Janssen, the pharmaceutical sector of Johnson & Johnson.

Rick Lindberg was executive director and head of Pfizer’s Centers for Therapeutic Innovation–California until 2017. He was responsible for research sites in San Francisco and other locations.

Phanes was founded in July 2016 and is led by a team with drug discovery and development experience at global pharma and biotech companies, including Pfizer, Amgen, and J&J.

11535 Sorrento Valley Road, Suite 400 San Diego, CA 92121 PLEASE EMAIL US: Email: operations@phanestx.com

Phanes Therapeutics is a clinical-stage biotech company focused on immuno-oncology drug discovery and development. It is conducting three Phase 2 trials with spevatamig, peluntamig, and mavrostobart; spevatamig and peluntamig have FDA orphan drug and Fast Track designations.